Jiajia Hu, Jiawei Zhang, Meng Yu, Zukai Liu, Yan Zou, Liwen Hong, Tianyu Zhang, Jing Sun, Minhua Zheng, Xuekai Zhu, Zhengting Wang, Sanhong Liu
Acta biochimica et biophysica Sinica 2021 Oct 12Many patients with cancers have low levels of CD4+ in their peripheral blood. However, the molecular mechanism is still unclear. Here, we found that the blood levels of miR-221 and miR-222 were dramatically increased in patients with colorectal cancer (CRC), and both circulating miR-211 and miR-222 served as sensitive diagnostic markers with an area under the curve of 0.8790 and 0.9148, respectively. Transfection of either miR-221 or miR-222 resulted in the reduction of the surface CD4 antigen level but not the surface CD8 antigen level. The luciferase reporter assay showed that miR-221/222 directly regulated CD4 expression in human primary T cells. These data showed that miR-221/222 levels were upregulated in the blood of patients with CRC and that the expression of CD4 in human primary T cells was inhibited by miR-221/222. These findings provide a novel strategy for modulating the number of CD4+ T cells in the blood and further adjusting the microenvironment suitable for immunotherapy. © The Author(s) 2021. Published by Oxford University Press on behalf of the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Jiajia Hu, Jiawei Zhang, Meng Yu, Zukai Liu, Yan Zou, Liwen Hong, Tianyu Zhang, Jing Sun, Minhua Zheng, Xuekai Zhu, Zhengting Wang, Sanhong Liu. Circulating miR-221/222 reduces CD4+ T cells by inhibiting CD4 expression in colorectal cancer. Acta biochimica et biophysica Sinica. 2021 Oct 12;53(10):1367-1376
PMID: 34357372
View Full Text